Invitae Co. (NYSE:NVTA – Get Rating) has been given a consensus rating of “Hold” by the twelve research firms that are presently covering the company, Marketbeat.com reports. Five analysts have rated the stock with a sell recommendation and five have assigned a hold recommendation to the company. The average 1-year price objective among analysts that […]
StockNews.com initiated coverage on shares of Invitae (NYSE:NVTA – Get Rating) in a research note issued to investors on Thursday morning. The brokerage issued a sell rating on the medical research company’s stock. Several other research analysts also recently issued reports on NVTA. The Goldman Sachs Group downgraded shares of Invitae from a neutral rating […]
Invitae Co. (NYSE:NVTA – Get Rating) CEO Kenneth D. Knight sold 45,432 shares of the stock in a transaction dated Tuesday, May 16th. The stock was sold at an average price of $1.20, for a total transaction of $54,518.40. Following the completion of the transaction, the chief executive officer now owns 1,671,610 shares of the […]
Raymond James downgraded shares of Invitae (NYSE:NVTA – Get Rating) from a market perform rating to an underperform rating in a report issued on Monday morning, The Fly reports. A number of other equities analysts also recently commented on NVTA. Piper Sandler reduced their price objective on shares of Invitae from $2.25 to $1.75 and […]
Invitae Co. (NYSE:NVTA – Get Rating) insider Robert L. Nussbaum sold 26,476 shares of the company’s stock in a transaction on Tuesday, May 16th. The shares were sold at an average price of $1.20, for a total value of $31,771.20. Following the completion of the sale, the insider now owns 576,431 shares of the company’s […]